• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by CONMED Corporation

    6/18/25 11:56:27 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CNMD alert in real time by email
    11-K 1 cnmd11-k2024.htm 11-K Document

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
     
    WASHINGTON, D.C. 20549
     
    Form 11-K
     
    ý  Annual Report Pursuant To Section 15(d) Of
    The Securities Exchange Act of 1934
    For the fiscal year ended December 31, 2024
     
    OR
     
    ¨  Transition Report Pursuant To Section 15(d) Of
    The Securities Exchange Act of 1934
    For the transition period from ________ to _________
     
    Commission File Number 001-39218
     
    (A) Full title of the plan and the address
    of the plan, if different from that of
    the issuer named below:
     
    CONMED CORPORATION
    Retirement Savings Plan
     
    (B) Name of issuer of the securities held
    pursuant to the plan and the address
    of its principal executive office:
     
    CONMED CORPORATION
    11311 Concept Blvd
    Largo, Florida 33773





    CONMED Corporation
    Retirement Savings Plan
    Index to Financial Statements
    December 31, 2024 and 2023

     Page
      
    Report of Independent Registered Public Accounting Firm
    1
      
    Financial Statements: 
      
    Statements of Net Assets Available for Benefits as of December 31, 2024 and 2023
    2
      
    Statement of Changes in Net Assets Available for Benefits for the Year Ended December 31, 2024
    3
      
    Notes to Financial Statements
    4
      
    Supplemental Schedules: *
     
      
    Schedule H, line 4i - Schedule of Assets (Held at End of Year) as of December 31, 2024
    9
    Schedule H, line 4a - Schedule of Delinquent Participant Contributions for the Year Ended December 31, 2024
    10
      
    Signatures
    11
    *All other schedules required by 29 CFR 2520.103-10 of the Department of Labor’s Rules and Regulations for Reporting and Disclosure under ERISA have been omitted because they are not applicable.
     




    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
     
    To the Participants and Administrator of
    CONMED Corporation Retirement Savings Plan
     
    Opinion on the Financial Statements
    We have audited the accompanying statements of net assets available for benefits of CONMED Corporation Retirement Savings Plan (the Plan) as of December 31, 2024 and 2023, the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes to the financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.
     
    Basis for Opinion
    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental Information
    The supplemental information in the accompanying schedule of assets (held at end of year) as of December 31, 2024 and schedule of delinquent participant contributions for the year ended December 31, 2024 has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is presented for the purpose of additional analysis and is not a required part of the financial statements but includes supplemental information required by the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. The supplemental information is the responsibility of the Plan's management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information in the accompanying schedules, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information in the accompanying schedules is fairly stated in all material respects in relation to the financial statements as a whole.


     
    /s/Insero & Co. CPAs, LLP 
     Certified Public Accountants 
     We have served as the Plan’s auditor since 2004.
     Rochester, New York 
     June 18, 2025 
     

    1



    CONMED Corporation
    Retirement Savings Plan
     
    Statements of Net Assets Available for Benefits
    December 31, 2024 and 2023
     20242023
    Assets  
      
    Investments, at Fair Value$336,728,803 $307,809,880 
    Notes Receivable from Participants5,049,944 5,064,129 
              Net Assets Available for Benefits$341,778,747 $312,874,009 
     
    The accompanying notes are an integral part of the financial statements.
     
    2


    CONMED Corporation
    Retirement Savings Plan
     
    Statement of Changes in Net Assets Available for Benefits
    Year Ended December 31, 2024
    Additions to net assets attributed to: 
         Net appreciation in fair value of investments$24,373,202 
         Interest and dividends15,351,906 
         Interest on notes receivable from participants349,370 
         Contributions: 
              Participants17,221,391 
              Employer7,454,226 
      
              Total additions64,750,095 
      
    Deductions from net assets attributed to: 
         Administrative expenses255,852 
         Distributions to participants35,589,505 
      
              Total deductions35,845,357 
      
              Net increase
    28,904,738 
    Net assets available for benefits at beginning of year312,874,009 
     
              Net assets available for benefits at end of year$341,778,747 
     
    The accompanying notes are an integral part of the financial statements.
     

    3


    CONMED Corporation
    Retirement Savings Plan
    Notes to Financial Statements
    December 31, 2024 and 2023
     

    Note 1 - Establishment and Description of Plan

        Effective January 1992, CONMED Corporation (the "Company") established the CONMED Corporation Retirement Savings Plan (the "Plan"). The Plan is a defined contribution plan covering all employees of the Company and its subsidiaries who meet the service requirements set forth in the Plan document. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 ("ERISA"). The following brief description of the Plan is provided for general information purposes only. Participants should refer to the Plan agreement for more complete information.
     
    Administration of the Plan
     
        The Company serves as Plan Administrator with full power, authority and responsibility to control and manage the operation and administration of the Plan.
     
    Contributions
     
        A participant can contribute 1 to 50 percent of his or her annual compensation, as defined, up to the maximum annual limitations as provided by the Internal Revenue Code (“IRC”). Participants who have attained age 50 before the end of the Plan year are eligible to make catch-up contributions. Participants may also contribute amounts representing distributions from other qualified plans. The Plan includes an auto-enrollment provision whereby all newly eligible employees, defined as having completed 90 days of employment, are automatically enrolled in the Plan unless they affirmatively elect not to participate in the Plan. Automatically enrolled participants have their deferral rate set at 3% of eligible compensation and their contribution invested in a designated balanced fund until changed by the participant. The pre-tax contribution of an employee who is contributing less than 7% of the employee’s annual compensation, as defined in the plan document, automatically increases annually in 1% increments until the employee’s pre-tax contribution election reaches 7% of annual compensation, provided the employee has not elected to opt-out of the automatic increase feature. Employees with an initial enrollment date between July 2nd and December 31st in a given plan year that have not elected to opt-out of this election will not be subject to this annual increase until the following plan year.

        The Company matches 100% of each participant's contribution up to a maximum of 7% of participant compensation. Effective February 13, 2023, the Plan was amended to cap the annual fixed Company match to $7,000. The Company, in its sole discretion, may elect to make a discretionary matching contribution to the Plan. Forfeitures of terminated participants’ non-vested accounts are used to reduce employer contributions or to pay Plan expenses. Forfeitures reduced employer contributions by $1,507,019 in 2024. At December 31, 2024 and 2023, forfeited non-vested accounts totaled $141,228 and $13,137, respectively.
        
    Participant Accounts

        A participant can allocate their account among various investment funds. Each participant's account is credited with the participant's contribution, the Company's contribution, and an allocation of the earnings and losses for the participant's particular investment funds and charged with withdrawals and an allocation of administrative expenses. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.
        
    Vesting
     
        Each participant is immediately vested in his or her voluntary contributions plus earnings thereon. A participant vests at 20% per year of service and becomes fully vested in the remainder of his or her account upon the completion of five years of service.
     
    4


    Investment Options
     
        Participants are allowed to invest in a variety of investment choices as more fully described in the Plan literature. In addition, participants have access to a self-directed brokerage account. Through this account, a participant has access to investments including common stock, mutual funds, preferred stock, corporate bonds and money market funds. Participants may change their investment options on a daily basis.
     
    Notes Receivable from Participants
     
        A participant may obtain a loan between $500 and $50,000, limited to 50 percent of his or her vested account balance. A participant is eligible to have up to two general loans at one time and one home loan outstanding for a combined total of three loans outstanding at any one time. Each loan bears interest at prime plus 1 percent and is secured by the balance in the participant's account. Repayment is required over a period not to exceed five years or up to fifteen years where the loan is for the purchase of a primary residence. Loan repayments are allocated among the investment options consistent with the participant's contribution investment election.
     
    Payment of Benefits
     
        Participants or their beneficiaries are eligible to receive benefits under the Plan upon normal retirement, death, total and permanent disability or termination for any reason including those previously mentioned. The Plan also provides for withdrawals by participants prior to termination. Benefits are payable in accordance with the Plan agreement.
     
    Plan Termination
     
        While the Company anticipates and believes that the Plan will continue, it reserves the right to discontinue the Plan subject to the provisions of ERISA. In the event of Plan termination, participants will become 100 percent vested in their accounts.

    Note 2 - Significant Accounting Policies
     
    Basis of Accounting
     
        The accounts of the Plan are maintained on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.
     
    Notes Receivable from Participants
     
        Notes receivable from participants are measured at their unpaid principal balance plus any accrued but unpaid interest. Delinquent notes receivable from participants are reclassified as distributions based upon the terms of the Plan document.
     
    Investment Valuation and Income Recognition
     
        Investments are reported at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
     
        The Financial Accounting Standards Board ("FASB") guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements. The FASB defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction. The framework requires an entity to maximize the use of observable inputs when measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:
     
    Level 1 - Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
     
    Level 2 - Inputs to the valuation methodology include:

    5


    •Quoted prices for similar assets or liabilities in active markets;
    •Quoted prices for identical or similar assets or liabilities in inactive markets;
    •Inputs other than quoted prices that are observable for the asset or liability;
    •Inputs that are derived principally from, or corroborated by, observable market data by correlation or other means.

        If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.
     
    Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
     
        The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

        Following is a description of the valuation methodologies used for investments measured at fair value. There have been no changes in the methodologies used at December 31, 2024 and 2023.
     
    Mutual Funds
     
        These investments are public investment vehicles valued using the Net Asset Value (“NAV”) provided by the administrator of the fund. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The NAV is a quoted price in an active market and classified within level 1 of the valuation hierarchy.

    Self-directed Brokerage Account
     
        The self-directed brokerage account consists primarily of common stock, mutual funds, preferred stock, corporate bonds and money market funds. Common stock, preferred stock and corporate bonds are valued at the closing price reported on the investments' respective stock exchange or active market. Mutual funds and money market funds are valued using NAV. All investments are classified within level 1 of the valuation hierarchy.

    Common Stock
     
        Common stock is valued at the closing price reported on the common stock’s respective stock exchange and is classified within level 1 of the valuation hierarchy.

    Money Market Funds
     
        These investments are public investment vehicles valued using NAV. The money market funds are classified within level 1 of the valuation hierarchy.
     
    Common Collective Trust
     
        This investment is valued at NAV provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value and is obtained from information provided by the investment advisor using the audited financial statements of the common collective trust at year end. Under the practical expedient, the investment is not classified in the valuation hierarchy.
     
        The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

    6


        The following table sets forth, by level within the fair value hierarchy, the Plan's investments, at fair value:
      
     Investments, at Fair Value as of
    December 31, 2024
     Level 1Total
    Mutual Funds$303,974,251 $303,974,251 
    Self-directed Brokerage Account12,329,390 12,329,390 
    Common Stock4,886,191 4,886,191 
    Money Market Funds7,894,825 7,894,825 
    Investments measured at fair value329,084,657 329,084,657 
    Investments measured at NAV as a practical expedient (a)
     7,644,146 
    Total investments, at fair value $336,728,803 
     
     Investments, at Fair Value as of
    December 31, 2023
     Level 1Total
    Mutual Funds$269,676,667 $269,676,667 
    Self-directed Brokerage Account12,992,002 12,992,002 
    Common Stock8,318,357 8,318,357 
    Money Market Funds8,448,107 8,448,107 
    Investments measured at fair value299,435,133 299,435,133 
    Investments measured at NAV as a practical expedient (a)
     8,374,747 
    Total investments, at fair value $307,809,880 
     
        (a) In accordance with Subtopic 820-10, certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Statements of Net Assets Available for Benefits.
     
        Purchases and sales of securities are recorded on a trade-date basis. Dividends are recorded on the ex-dividend date. Interest is recorded on the accrual basis. Net appreciation includes the Plan's gains and losses on investments bought and sold as well as held during the year.
     
    Contributions
     
        Participant contributions and matching employer contributions are recorded in the period during which the Company makes payroll deductions from the participants’ earnings.
     
    Administrative Expenses
     
        The Plan’s administrative expenses are paid by either the Plan or the Plan’s Sponsor as defined in the Plan document.
     
    Payment of Benefits
     
        Benefit payments to participants are recorded upon distribution.
     
    Use of Estimates
     
        The preparation of the Plan’s financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and changes therein, and disclosures of contingent assets and liabilities. The Company is not aware of any specific events or circumstance that would require disclosure or an update to estimates or judgments or a revision of the carrying value
    7


    of the Plan's assets or liabilities through June 18, 2025. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ from those estimates.
     
    Risks and Uncertainties
     
        The Plan invests in various investment securities. Investment securities are exposed to various risks, such as interest rate, market, and credit risks. Market risks include global events which could impact the value of investment securities, such as inflation, a pandemic or international conflict. Due to the level of risk associated with these investments, it is at least reasonably possible that changes in their values will occur in the near term and that such changes could materially affect participants’ account balances and the amounts reported in the Statements of Net Assets Available for Benefits.

    Note 3 - Income Tax Status

        The trust established under the Plan to hold the Plan’s assets is qualified pursuant to the appropriate section of the IRC, and, accordingly, the trust’s net investment income is exempt from income taxes. The Plan has obtained a favorable tax determination letter, dated August 2, 2017, from the Internal Revenue Service (“IRS”). The Plan Administrator and the Plan’s tax counsel believe that the Plan, as amended, is designed, and is currently being operated, in compliance with the applicable requirements of the IRC.
        
        Accounting principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan Administrator has analyzed the tax positions taken by the Plan and has concluded that as of December 31, 2024, there are no uncertain positions taken, or expected to be taken, that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

    Note 4 - Transactions with Parties-in-Interest

        As of December 31, 2024 and 2023, the Plan held certain securities issued by the Company as follows:
     
     December 31, 2024December 31, 2023
    Number
    of
    Shares
    Fair
    Value
    Number
    of
    Shares
     Fair
    Value
    CONMED Corporation    
         Common Stock71,394 $4,886,191 75,960 $8,318,357 

        In addition, certain assets of the Plan are invested in funds managed by Fidelity Management Trust Company ("Fidelity"). Fidelity is the trustee of the Plan and, therefore, is considered to be a party-in-interest. Notes receivable from participants also qualify as party-in-interest transactions.

    Note 5 - Prohibited Transactions

        During 2024, the Company failed to deposit $65,027 and $20,564 of participant deferrals and loan repayments, respectively, within the required timeframe as stated by the United States Department of Labor ("DOL"). The DOL considers late deposits to be prohibited transactions. The lost earnings on the participant deferrals and loan repayments were deposited during 2024.

    8


    CONMED Corporation
    Retirement Savings Plan
    Schedule H, line 4i - Schedule of Assets (Held at End of Year)
    December 31, 2024
    EIN: 16-0977505
    Plan Number: 005
     Current
    Identity of Issue/Description of InvestmentValue
      
    Fidelity 500 Index Fund**$39,543,711 
    Fidelity Freedom 2045 Fund - Class K**21,383,186 
    Fidelity Freedom 2050 Fund - Class K**20,224,507 
    Fidelity Freedom 2040 Fund - Class K**20,034,047 
    Fidelity Puritan Fund - Class K**19,541,622 
    Janus Henderson Enterprise Fund Class N18,272,234 
    Fidelity Freedom 2035 Fund - Class K**16,719,245 
    Fidelity Contrafund - Class K**15,763,803 
    Fidelity Freedom 2055 Fund - Class K**14,297,210 
    Fidelity Capital Appreciation Fund Class K**12,981,574 
    Participant - Directed Brokerage Link Account12,329,390 
    Fidelity Freedom 2030 Fund - Class K**12,020,893 
    Fidelity Low-Priced Stock Fund - Class K**10,841,948 
    MFS Value R610,520,459 
    Fidelity Freedom 2025 Fund - Class K**9,408,599 
    Fidelity Freedom 2060 Fund - Class K**9,197,113 
    Fidelity Investment Grade Bond Fund**8,246,326 
    Fidelity Diversified International Fund - Class K**7,989,823 
    Fidelity Government Money Market Fund**7,893,223 
    Fidelity Managed Income Portfolio Class 1**7,644,146 
    T. Rowe Price Dividend Growth Fund - I Class6,727,364 
    CONMED Corporation Common Stock **4,886,191 
    Fidelity Extended Market Index Fund**4,518,476 
    Fidelity Freedom 2020 Fund - Class K**4,422,859 
    Fidelity U.S. Bond Index Fund**4,193,748 
    Fidelity Global ex U.S. Index Fund**3,811,616 
    Macquarie Small Cap Value Fund R63,573,296 
    Allspring Emerging Markets Equity Fund R62,833,628 
    Fidelity Freedom 2065 Fund - Class K**2,617,756 
    JP Morgan U.S. Small Company Fund Class R62,439,738 
    Fidelity Freedom Income Fund - Class K**831,980 
    Fidelity Freedom 2015 Fund - Class K**577,874 
    Fidelity Freedom 2010 Fund - Class K**439,616 
    Interest Bearing Cash Accounts1,602 
    Notes receivable from participants, interest rates from 
    4.25% to 9.50% and maturities from 2025 to 2040**
    5,049,944 
      
     $341,778,747 
    ** Denotes party-in-interest
    9


    CONMED Corporation
    Retirement Savings Plan
    Schedule H, line 4a - Schedule of Delinquent Participant Contributions
    Year Ended December 31, 2024
    EIN: 16-0977505
    Plan Number: 005
     
    Participant Contributions Transferred Late to Plan
    Total that Constitute Nonexempt Prohibited Transactions
    Total Fully Corrected Under Voluntary Fiduciary Correction Program (VFCP) and Prohibited Transaction Exemption 2002-51
    Year
    Check here if Late Participant Loan Repayments are Included: ☑
     Contributions Not Corrected
    Contributions Corrected Outside VFCP
    Contributions Pending Correction in VFCP
    2024$85,591 $— $— $— $85,591 
    10


    SIGNATURES
     
        Pursuant to the requirements of the Securities Exchange Act of 1934, the Plan Administrator has duly caused this Annual Report to be signed by the undersigned hereunto duly authorized.
     
     CONMED CORPORATION
     Retirement Savings Plan
      
     By:/s/ Todd W. Garner
     Name:Todd W. Garner
     Title:
    Executive Vice President, Finance & Chief Financial Officer
     
    Date: June 18, 2025
     

    11
    Get the next $CNMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CNMD

    DatePrice TargetRatingAnalyst
    6/12/2025Buy → Hold
    Needham
    4/28/2025$55.00Buy → Hold
    Stifel
    2/6/2025$85.00 → $70.00Overweight → Neutral
    Analyst
    2/1/2024$119.00 → $129.00Buy
    Needham
    5/22/2023$140.00Buy
    CL King
    3/27/2023$124.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/21/2023$96.00Equal Weight
    Wells Fargo
    10/12/2022$85.00Hold
    Jefferies
    More analyst ratings

    $CNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CONMED downgraded by Needham

      Needham downgraded CONMED from Buy to Hold

      6/12/25 7:52:09 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED downgraded by Stifel with a new price target

      Stifel downgraded CONMED from Buy to Hold and set a new price target of $55.00

      4/28/25 8:32:52 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED downgraded by Analyst with a new price target

      Analyst downgraded CONMED from Overweight to Neutral and set a new price target of $70.00 from $85.00 previously

      2/6/25 7:05:01 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bronson David M bought $97,322 worth of shares (1,350 units at $72.09), increasing direct ownership by 9% to 16,460 units (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/14/24 3:37:54 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Schwarzentraub Barbara J bought $99,873 worth of shares (1,442 units at $69.26) (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/10/24 5:29:04 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Aronson Martha Goldberg bought $141,960 worth of shares (2,000 units at $70.98) (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/8/24 4:20:48 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CONMED Corporation

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      11/13/24 4:22:22 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CONMED Corporation

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      11/12/24 12:53:28 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by CONMED Corporation (Amendment)

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      2/13/24 5:02:29 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    SEC Filings

    See more
    • SEC Form 11-K filed by CONMED Corporation

      11-K - CONMED Corp (0000816956) (Filer)

      6/18/25 11:56:27 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - CONMED Corp (0000816956) (Filer)

      6/16/25 4:31:25 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SD filed by CONMED Corporation

      SD - CONMED Corp (0000816956) (Filer)

      5/29/25 4:40:52 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CONMED Corporation to Announce Second Quarter 2025 Financial Results on July 30, 2025

      CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the second quarter 2025 after the market close on Wednesday, July 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medic

      7/2/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

      CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

      5/21/25 7:03:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces Quarterly Cash Dividend

      CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on certain as

      5/21/25 7:00:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schwarzentraub Barbara J converted options into 479 shares, increasing direct ownership by 12% to 4,344 units (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      6/4/25 5:42:25 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Kaye Mark

      4 - CONMED Corp (0000816956) (Issuer)

      6/4/25 5:41:24 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Concannon Brian converted options into 479 shares, increasing direct ownership by 5% to 10,116 units (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      6/4/25 5:40:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Financials

    Live finance-specific insights

    See more
    • CONMED Corporation to Announce Second Quarter 2025 Financial Results on July 30, 2025

      CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the second quarter 2025 after the market close on Wednesday, July 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medic

      7/2/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces Quarterly Cash Dividend

      CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on certain as

      5/21/25 7:00:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces First Quarter 2025 Financial Results

      CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant currency. Domestic revenue increased 4.2% year-over-year. International revenue increased 1.2% year-over-year as reported and 3.4% in constant currency. Diluted net earnings per share (GAAP) were $0.19, compared to diluted net earnings per share (GAAP) of $0.63 in the first quarter of 2024. Adjusted diluted net earnings per share(1) were $0.95, compared to adjusted diluted net earnings per share of $0.79 in the first quarter of 2024. "We had a good start t

      4/30/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Leadership Updates

    Live Leadership Updates

    See more
    • CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

      CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

      5/21/25 7:03:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

      CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

      2/9/21 4:01:00 PM ET
      $CSII
      $MEI
      $CNMD
      Medical/Dental Instruments
      Health Care
      Electrical Products
      Technology